umbralisib

03/01/2023 - "Umbralisib is one of the latest PI3Kδ inhibitors in clinical trials for several hematologic cancer indications. "
01/01/2018 - "The aim of this first-in-human phase 1 study was to establish the safety and preliminary activity profile of umbralisib in patients with haematological malignancies. "
12/14/2021 - "The favorable long-term tolerability profile and low rates of immune-mediated toxicities support the potential use of umbralisib for the benefit of a broad population of patients with lymphoid malignancies."
12/14/2021 - "Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies."
01/01/2018 - "Umbralisib was well tolerated and showed preliminary signs of activity in patients with relapsed or refractory haematological malignancies. "

04/01/2022 - "Umbralisib, as the 4th iteration in this PI3K-inhibitor class for relapsed/refractory indolent B-cell lymphoma (iB-NHL), appears comparably active but may have improved tolerability. "

01/01/2022 - " receiving umbralisib to treat lymphomas should be evaluated closely for adverse effects. "
01/01/2021 - "Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma."
01/01/2019 - "Umbralisib: Treatment for a Rare Lymphoma?"
01/01/2019 - "The PI3Kδ inhibitor umbralisib may be a promising therapy for patients with relapsed/refractory marginal zone lymphoma: In the phase IIb UNITY-NHL trial, the drug elicited a response rate of 55%. "
04/01/2022 - "The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma."

11/01/2021 - "We present a grade-3 colitis that can be attributed to umbralisib-mediated immune toxicity in a patient with chronic lymphocytic leukemia at the therapeutic dose."
12/01/2021 - "Umbralisib and ublituximab: an upcoming regimen for chronic lymphocytic leukemia."
01/01/2021 - "In this multicohort, open-label, phase IIb study, 208 patients with R/R marginal zone, follicular, or small lymphocytic lymphoma (MZL, FL, or SLL) unresponsive to prior treatments (≥ 1 MZL; ≥ 2 FL/SLL), including ≥ 1 anti-CD20-based therapy, were administered umbralisib 800 mg orally once daily until disease progression, unacceptable toxicity, or study withdrawal. "
11/21/2019 - "Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia."
10/23/2023 - "Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia."

01/01/2021 - "Umbralisib showed efficacy and in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL)."
11/21/2019 - "Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia."
02/01/2019 - "Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial."
02/01/2019 - "The combination of ublituximab, umbralisib, and ibrutinib seems to be tolerable and is associated with encouraging activity in advanced chronic lymphocytic leukaemia and B-cell non-Hodgkin lymphoma. "
11/21/2019 - "The safety of the next-generation compounds umbralisib, a PI3K-δ inhibitor, plus ublituximab, an anti-CD20 monoclonal antibody (combination referred to as U2), was evaluated in patients with chronic lymphocytic lymphoma (CLL) or non-Hodgkin lymphoma (NHL) in this phase 1/1b study. "